Roche Unveils New Data on Multiple Sclerosis Treatment

Roche Holding AG said Tuesday that its Ocrevus treatment reduces the risk of needing a walking aid in relapsing multiple sclerosis patients by 49%, according to new data.
The analysis from six years of phase 3 open-label extension studies shows that Ocrevus reduces the risk of disease and disability progression for relapsing and primary progressive multiple sclerosis, the Swiss pharmaceutical giant said.
https://www.marketscreener.com/ROCHE-HOLDING-AG-9364975/news/Roche-Unveils-New-Data-on-Multiple-Sclerosis-Treatment-30484578/